Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Overview of Castleman diseaseBlood, 2020-04, Vol.135 (16), p.1353-1364 [Peer Reviewed Journal]2020 American Society of Hematology ;2020 by The American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2019000931 ;PMID: 32106302Full text available |
|
2 |
Material Type: Article
|
Novel insights and therapeutic approaches in idiopathic multicentric Castleman diseaseBlood, 2018-11, Vol.132 (22), p.2323-2330 [Peer Reviewed Journal]2018 American Society of Hematology ;2018 by The American Society of Hematology. ;2018 by The American Society of Hematology 2018 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2018-05-848671 ;PMID: 30487129Full text available |
|
3 |
Material Type: Article
|
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood, 2017-03, Vol.129 (12), p.1646-1657 [Peer Reviewed Journal]2017 American Society of Hematology ;2017 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2016-10-746933 ;PMID: 28087540Full text available |
|
4 |
Material Type: Article
|
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseThe Journal of clinical investigation, 2019-10, Vol.129 (10), p.4451-4463 [Peer Reviewed Journal]COPYRIGHT 2019 American Society for Clinical Investigation ;COPYRIGHT 2019 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Oct 2019 ;2019 American Society for Clinical Investigation 2019 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci126091 ;PMID: 31408438Full text available |
|
5 |
Material Type: Article
|
Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman diseaseBlood, 2017-03, Vol.129 (12), p.1658-1668 [Peer Reviewed Journal]2017 American Society of Hematology ;2017 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2016-11-748855 ;PMID: 28100459Full text available |
|
6 |
Material Type: Article
|
A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseasesOrphanet journal of rare diseases, 2023-04, Vol.18 (1), p.75-75, Article 75 [Peer Reviewed Journal]2023. The Author(s). ;COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1750-1172 ;EISSN: 1750-1172 ;DOI: 10.1186/s13023-023-02678-6 ;PMID: 37041585Full text available |
|
7 |
Material Type: Article
|
Novel insights and therapeutic approaches in idiopathic multicentric Castleman diseaseHematology, 2018-11, Vol.2018 (1), p.318-3252018 by The American Society of Hematology. All rights reserved. ;2018 by The American Society of Hematology. All rights reserved. 2018 American Society of Hematology ;ISSN: 1520-4391 ;EISSN: 1520-4383 ;DOI: 10.1182/asheducation-2018.1.318 ;PMID: 30504327Full text available |
|
8 |
Material Type: Article
|
Increased mTOR activation in idiopathic multicentric Castleman diseaseBlood, 2020-05, Vol.135 (19), p.1673-1684 [Peer Reviewed Journal]2020 American Society of Hematology ;2020 by The American Society of Hematology. ;2020 by The American Society of Hematology 2020 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2019002792 ;PMID: 32206779Full text available |
|
9 |
Material Type: Article
|
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman diseaseNature communications, 2022-11, Vol.13 (1), p.7236-7236, Article 7236 [Peer Reviewed Journal]2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-022-34873-7 ;PMID: 36433996Full text available |
|
10 |
Material Type: Article
|
Sharing is caring: a call for a new era of rare disease research and developmentOrphanet journal of rare diseases, 2022-10, Vol.17 (1), p.389-389, Article 389 [Peer Reviewed Journal]2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1750-1172 ;EISSN: 1750-1172 ;DOI: 10.1186/s13023-022-02529-w ;PMID: 36303170Full text available |
|
11 |
Material Type: Article
|
Cytokine StormNew England Journal of Medicine, 2020-12, Vol.383 (23), p.2255-2273 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMra2026131 ;PMID: 33264547Digital Resources/Online E-Resources |
|
12 |
Material Type: Article
|
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseBlood advances, 2020-12, Vol.4 (23), p.6039-6050 [Peer Reviewed Journal]2020 American Society of Hematology ;2020 by The American Society of Hematology. ;2020 by The American Society of Hematology 2020 ;ISSN: 2473-9529 ;EISSN: 2473-9537 ;DOI: 10.1182/bloodadvances.2020003334 ;PMID: 33284946Full text available |
|
13 |
Material Type: Article
|
Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent eraOrphanet journal of rare diseases, 2019-07, Vol.14 (1), p.173-173, Article 173 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;The Author(s). 2019 ;ISSN: 1750-1172 ;EISSN: 1750-1172 ;DOI: 10.1186/s13023-019-1145-y ;PMID: 31296233Full text available |
|
14 |
Material Type: Article
|
Correction to: Sharing is caring: a call for a new era of rare disease research and developmentOrphanet journal of rare diseases, 2023-01, Vol.18 (1), p.15-15, Article 15 [Peer Reviewed Journal]COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1750-1172 ;EISSN: 1750-1172 ;DOI: 10.1186/s13023-023-02613-9 ;PMID: 36691034Full text available |
|
15 |
Material Type: Article
|
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseasePloS one, 2019-06, Vol.14 (6), p.e0218660-e0218660 [Peer Reviewed Journal]COPYRIGHT 2019 Public Library of Science ;2019 Nabel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Nabel et al 2019 Nabel et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0218660 ;PMID: 31242229Full text available |
|
16 |
Material Type: Article
|
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modellingFrontiers in immunology, 2022-07, Vol.13, p.919489-919489 [Peer Reviewed Journal]Copyright © 2022 Rossi, Chiang, Lu, Levon, van Rhee, Kanhai, Fajgenbaum and Klein. ;Attribution ;Copyright © 2022 Rossi, Chiang, Lu, Levon, van Rhee, Kanhai, Fajgenbaum and Klein 2022 Rossi, Chiang, Lu, Levon, van Rhee, Kanhai, Fajgenbaum and Klein ;ISSN: 1664-3224 ;EISSN: 1664-3224 ;DOI: 10.3389/fimmu.2022.919489 ;PMID: 35928820Full text available |
|
17 |
Material Type: Article
|
Siltuximab: a targeted therapy for idiopathic multicentric Castleman diseaseImmunotherapy, 2016-01, Vol.8 (1), p.17-26 [Peer Reviewed Journal]Future Medicine Ltd ;Copyright Future Medicine Ltd Jan 2016 ;ISSN: 1750-743X ;EISSN: 1750-7448 ;DOI: 10.2217/imt.15.95 ;PMID: 26634298Full text available |
|
18 |
Material Type: Article
|
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman diseaseAnnals of hematology, 2018-09, Vol.97 (9), p.1641-1647 [Peer Reviewed Journal]Springer-Verlag GmbH Germany, part of Springer Nature 2018 ;Annals of Hematology is a copyright of Springer, (2018). All Rights Reserved. ;ISSN: 0939-5555 ;EISSN: 1432-0584 ;DOI: 10.1007/s00277-018-3347-0 ;PMID: 29732477Full text available |
|
19 |
Material Type: Article
|
Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndromeAnnals of hematology, 2017-03, Vol.96 (3), p.497-500 [Peer Reviewed Journal]Springer-Verlag Berlin Heidelberg 2016 ;Annals of Hematology is a copyright of Springer, 2017. ;ISSN: 0939-5555 ;EISSN: 1432-0584 ;DOI: 10.1007/s00277-016-2875-8 ;PMID: 27853835Full text available |
|
20 |
Material Type: Article
|
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic ReviewInfectious diseases and therapy, 2020-09, Vol.9 (3), p.435-449 [Peer Reviewed Journal]The Author(s) 2020 ;The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2193-8229 ;EISSN: 2193-6382 ;DOI: 10.1007/s40121-020-00303-8 ;PMID: 32462545Full text available |